Samsung Bioepis Highlights Consistent Efficacy of SB16 (OBODENCE®; Denosumab) Across Osteoporosis Patient Subgroups at WCO-IOF-ESCEO 2026

AI Briefing

• – SB16 (OBODENCE) biosimilar shows consistent efficacy across various osteoporosis patient subgroups
• – Data to be presented at WCO-IOF-ESCEO 2026 in Prague
• – Supports Samsung Bioepis' position in the market with a high-quality biosimilar alternative to Prolia